Acrivon Therapeutics Inc
Veridion Score
Composite trend over time
Why is ACRV moving today?
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ACRV.
ACRV insider activity
Acrivon Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net buying: $6.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | 2026-05-21 | Blume-Jensen Peter | Insider | sell | $1.79 | 13,729 | 2,245,317 | $25K | SEC Form 4 |
| 2026-05-18 | 2026-05-14 | Peterson Katharine | Insider | sell | $1.92 | 99 | 3,907 | $190 | SEC Form 4 |
| 2026-05-18 | 2026-05-14 | Miller Mary | Insider | sell | $1.92 | 184 | 32,937 | $353 | SEC Form 4 |
| 2026-05-18 | 2026-05-14 | Gamelin Erick | Insider | sell | $1.92 | 404 | 14,408 | $776 | SEC Form 4 |
| 2026-05-18 | 2026-05-14 | Devroe Eric | Insider | sell | $1.92 | 613 | 73,972 | $1K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 33 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moACRV contract awards, year to date.
Public federal awards linked to this ticker.
ACRV lobbying filings, year to date.
Registered lobbying filings matched to Acrivon Therapeutics Inc.